MZT Matritech,

Matritech, Inc. (Amex: MZT), in compliance with the provisions of section 610(b) of the American Stock Exchange�s Company Guide, today announced that its independent registered public accounting firm included a going concern qualification in its report on Matritech�s consolidated financial statements for the fiscal year ended December 31, 2006. The qualification was included in the opinion as a result of the Company�s recurring losses from operations and negative cash flows. On December 8, 2006, the American Stock Exchange approved the Company�s plan to regain compliance with continued listing standards. The Company does not expect that this qualified opinion will change its program to meet Amex continued listing standards. For more information, please see Matritech�s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 27, 2007. About Matritech Matritech, a leading marketer and developer of protein-based diagnostic products for the early detection of cancer, is using its patented proteomics technology to develop diagnostics for the detection of a variety of cancers. The Company�s first two products, the NMP22� Test Kit and NMP22� BladderChek� Test, have been FDA approved for the monitoring and diagnosis of bladder cancer. The NMP22� BladderChek� Test is based on Matritech�s proprietary nuclear matrix protein (NMP) technology, which correlates levels of NMPs in body fluids to the presence of cancer. Beginning with a patent portfolio licensed exclusively from the Massachusetts Institute of Technology (MIT), Matritech�s patent portfolio has grown to 14 other U.S. patents. In addition to the NMP22 protein marker utilized in the NMP22� Test Kit and NMP22� BladderChek� Test, the Company has discovered other proteins associated with cervical, breast, prostate, and colon cancer. The Company�s goal is to utilize protein markers to develop, through its own research staff and through strategic alliances, clinical applications to detect cancer. More information about Matritech is available at www.matritech.com. Statement under the Private Securities Litigation Reform Act Any forward-looking statements in this press release including those related to the Company�s expectations regarding its ability to raise needed capital are subject to a number of risks and uncertainties, many of which are beyond the Company�s control. Please refer to the risk factors detailed in the Company�s periodic reports and registration statements as filed with the Securities and Exchange Commission. These forward-looking statements are neither promises nor guarantees. There can be no assurance that the Company�s plan will be accepted by the American Stock Exchange or that the Company will be able to make progress consistent with the plan if it is accepted. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Matritech undertakes no responsibility to revise or update any such forward-looking information.